Clinical Trial Update: Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity (SPIROTOX) [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating whether spironolactone can prevent cardiotoxicity caused by anthracycline chemotherapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiotoxicity
• Neoplasms

Drugs mentioned

• Spironolactone (spironolactone)

Snippet

Sponsor: University of Sao Paulo | Conditions: Cardiotoxicity, Neoplasms | Phase 4 | Status: UNKNOWN